NTRK1 and chromophobe renal cell carcinoma: Until the recent development of targeted therapies with multi-tyrosine kinase receptors inhibitors such as sunitinib and sorafenib, and although their effects are not long-lasting due to therapy-induced resistance, there was no efficient treatment for advanced human CRCC.